Management of angioedema. Guidelines of the Angiology Section of Slovak Medical Chamber (2013)

Česká verzia

Authors: Peter Gavorník ^1,2,3; Ľudovít Gašpar ^1,3; Andrej Dukát ^1,3
Authors place of work: II. interná klinika LF UK a UN Bratislava, Slovenská republika, prednosta doc. MUDr. Ľudovít Gašpar, CSc. ¹; Prvé angiologické pracovisko (PAP), vedúci lekár doc. MUDr. Peter Gavorník, PhD., mim. prof. ²; Sekcia angiológov Slovenskej lekárskej komory, predseda doc. MUDr. Peter Gavorník, PhD., mim. prof. ³
Published in the journal: Vnitř Lék 2014; 60(5-6): 490-498
Category: Guidelines

Summary

Angioedema is defined as a vascular reaction of the deep dermis/mucous and/or subcutaneous/submucosal tissues with localized vasodilatation and increased permeability of blood vessels resulting in tissue swelling. Angioedema can be mediated by bradykinin or mast cell mediators including histamine. Bradykinin-mediated angioedema can occur either on a hereditary (HAE) or acquired (AAE) basis, due to a deficiency/defect of C1 inhibitor (C1-INH) or not. Three forms of HAE have been defined: HAE due to C1-INH deficiency (type 1 HAE, HAE-1), characterized by low antigenic and functional C1-INH levels; HAE due to C1-INH dysfunction (type 2 HAE, HAE-2), characterized by normal (or elevated) antigenic but low functional C1-INH levels; and HAE with normal C1-INH antigenic and functional levels (HAE-3). Acquired C1-INH deficiency refers to patients with angioedema due to C1-INH deficiency on an acquired basis. There are a variety of acquired types of angioedema not due to C1-INH deficiency, and these may be bradykinin mediated (e.g. angiotensin-converting enzyme inhibitor-induced angioedema) or mast cell mediator histamine mediated (e.g. anaphylactic angioedema and urticarial angioedema). In recent years there have been several changes on how we look at the anaphylaxis. The spectrum of trigger factors and diagnostic and therapeutic algorithms has changed significantly. The anaphylaxis is regarded as any sudden severe hypersensitive reaction, which potentially can lead to death. Term anaphylactoid reaction is no more recommended to be used. Drug of first choice is adrenaline/epinephrine administered intramuscularly. Each patient at risk of angioedema should have a written individual rescue plan and knowledge how to use the first aid medicines.

Key words:
angioedema – AS SMC guidelines – CEAP (clinical-etiology-anatomy-patophysiology classification) – bradykinin

Zdroje

1. Craig T, Pürsün E, Bork K et al. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J 2012; 5(12): 182–199.

2. Sánchez-Borges M, Asero R, Ansodegui IJ et al (WAO Scientific and Clinical Issues Council). Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective. World Allergy Organ J 2012; 5(11): 125–147.

3. Thong B, Mirakian R, Castells M et al. World Allergy Organization International Survey on Diagnostic Procedures and Therapies in Drug Allergy/Hypersensitivity. World Allergy Organ J 2011; 4(12): 257–270.

4. Valent P, Klion AD, Rosenwasser LJ et al. International Consensus on: Eosinophil Disorders. World Allergy Organ J 2012; 5(12): 174–181.

5. Jeseňák M, Bánovčin P. Hereditárny angioedém na Slovensku – stále veľká neznáma? Pediatria pre prax 2013; 14(S1): 10–12.

6. Gavorník P. Etiopatogenéza a diferenciálna diagnóza edémových stavov. Kardiológia/Cardiology 2009; 18(2): 73–78.

7. Sampson HA, Munoz-Furlong A, Campbell RL et al. Second symposium on the definition management of anaphylaxis: summary report – Second National Institute of and Infectious Disease/Food Allergy Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117(2): 391–397.

8. Kadaňka Z, Peška S, Bednařík J. Orolinguální angioedém jako komplikace trombolytické léčby pacientů s akutní ischemickou cévní mozkovou příhodou. Neurológia pre prax 2013; 14(1): 50–52.

9. Simons FER, Ardusso LRF, M Beatrice Bilò MB et al. World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis. World Allergy Organ J 2011; 4(2): 13–37.

10. Boyce JA, Assa´ad A, Burks AW et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Report of the NIAID-Sponsored Expert Panel. J Allergy Clin Immunol 2010; 126(Suppl.6): S1-S58.

11. Zanichelli A. Medical management of hereditary angioedema: review for the internist. Gaz Med Ital 2013; 172(3): 185–199.

12. Zuberbier T, Asero R, Binslev-Jensen C et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64(10): 1417–1426.

13. Zuberbier T, Asero R, Binslev-Jensen C et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64(10): 1427–1443.

14. Adam Z, Tomiška M, Krejčí M et al. Diferenciální diagnostika eozinofilie. Vnitř Lék 2009; 55(Suppl 1): S125-S144.

15. Kestler A, Keyes L. Uvular Angioedema (Quincke’s Disease). N Engl J Med 2003; 349(9): 867.

16. Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359(10): 1027–1036.

17. Králičková P, Burešová E, Freiberger T et al. Hereditární angioedém – opomíjená diagnoza. Vnitř Lék 2010; 56(9): 927–931.

18. Zuraw BL, Busse PJ, White M et al. Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema. N Engl J Med 2010; 363(6): 513–522.

19. Cicardi M, Banerji A, Bracho F et al. Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema. N Engl J Med 2010; 363(6): 532–541.

20. Cicardi M, Levy RJ, McNeil DL et al. Ecallantide for the Treatment of Acute Attacks in Hereditary Angioedema. N Engl J Med 2010; 363(6): 523–531.

21. Maurer M, Rosén K, Hsieh HJ et al. Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. N Engl J Med 2013; 368(10): 924–935. Correction: N Engl J Med 2013; 368(24): 2340–2341.

22. Szturz P, Adam Z, Klabusay M et al. Schnitzlersyndrom: popis případu, zkušenosti s léčbou glukokortikoidy a preparátem anakinra (KineretTM) a sledování cytokinové odpovědi organizmu. Vnitř Lék 2011; 57(1): 97–112.

23. Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet 2012; 379(9814): 474–481.

24. Decker WW, Campbell RL, Manivannan V et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 2008; 122(6): 1161–1165.

25. Lin RY, Anderson AS, Shah SN et al. Increasing anaphylaxis hospitalizations in the first 2 decades of life: New York State, 1990–2006. Ann Allergy Asthma Immunol 2008; 101(4): 387–393.

26. Helbing A, Hurmi T, Mueller LR et al. Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940.000 inhabitants of the Swiss Canton Bern. Clin Exp Allergy 2004; 34(2): 285–290.

27. Benkelfat R, Gouin S, Larose G et al. Medication Errors in the management of anaphylaxis in a pediatric emergency department. J Emerg Med 2013; 45(3): 419–425.

28. Nowak R, Farrar JR, Brenner JR et al. Customizing anaphylaxis guidelines for emergency medicine. J Emerg Med 2013; 45(2): 299–306.

29. Goldflam K, Silvers CT. Exercise-induced anaphylaxis as a cause of syncope. J Emerg Med 2012; 43(4): 651–654.

30. Moellman JJ, Bernstein JA. Diagnosis and management of hereditary angioedema: An emergency medicine perspective. J Emerg Med 2012; 43(2): 391–400.

31. Hassen GW, Kalantari H, Parraga M et al. Fresh Frozen Plasma for Progressive and Refractory Angiotensin-Converting Enzyme Inhibitor-induced Angioedema. J Emerg Med 2013; 44(4): 764–772.

32. Druey KM, Greipp PR. Narrative Review: The Systemic Capillary Leak Syndrome. Ann Intern Med 2010; 153(2): 90–98.

33. Winters ME, Rosenbaum S, Vilke GM et al. Emergency Department Management of Patients with ACE-inhibitor Angioedema. J Emerg Med 2013; 45(5):775–780.

34. Lewis LM. Angioedema: Etiology, Pathophysiology, Current and Emerging Therapies. J Emerg Med 2013; 45(5):789–796.

35. Gavorník P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. Univerzita Komenského-Vydavateľstvo UK: Bratislava 2001. ISBN 80–223–1608–3.

36. Gavorník P. Angiológia pre všeobecných praktických lekárov. Flebológia. Dr. Josef Raabe: Bratislava 2013. ISBN 978–80–8140–083–4.

37. Nolan JP, Hazinski MF, Billi JE et al. 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Part 1 – Part 12. Resuscitation 2010. Dostupné z DOI: <http://doi: 10.1016/j.resuscitation.2010.08.022>.

38. Nolan JP, Soar J, Zideman DA et al (ERC Guidelines Writing Group). European Resuscitation Council Guidelines for Resuscitation 2010. Section 1 – Section 10. Resuscitation 2010; 81(10): 1219–1452.

39. Mundell WC, Kennedy CC, Szostek JH et al. Simulation technology for resuscitation training: a systematic review and meta-analysis. Resuscitation 2013; 84(9): 1174–1183.

40. Castells MC (ed). Anaphylaxis and Hypersensitivity Reactions. Humana Pr (Springer):New York 2011. ISBN 978–1-60327–950–5.

41. Hassen GW, Tu TJ, Wei DH et al. Does Angiotensin-Converting Enzyme Inhibitor Use Exacerbate Hereditary Angioedema? J Emerg Med 2013; 45(4): 602–608.

42. Siracusa MC, Kim BS, Spergel JM et al. Basophils and allergic inflammation. J Allergy Clin Immunol 2013; 132(4): 789–801.

43. Gavorník P, Gašpar Ľ, Dukát A. Nová klasifikácia, diagnóza a manažment angioedému. Odporúčania Angiologickej sekcie Slovenskej lekárskej komory (2013). Anestéziol intenzívna med 2013; 2(2): 71–76.